The University of Texas MD Anderson Cancer Center | Strategic Alliance Partners

Latest from The University of Texas MD Anderson Cancer Center


Axi-Cel Demonstrates Ongoing Survival Benefit in Relapsed/Refractory iNHL

December 11, 2021

Axicabtagene ciloleucel induced high response rates and improved survival in patients with relapsed/refractory follicular lymphoma or marginal zone lymphoma, according to updated data from the phase 2 ZUMA-5 trial.

MRD-Guided Treatment Represents the Future in CLL

December 06, 2021

William G. Wierda, MD, PhD, discussed the results of the phase 2 CAPTIVATE trial and the phase 1/2 TRANSCEND CLL 004 trial, and looked ahead to what the future holds for MRD in patients with CLL.

Enasidenib/Azacitidine Combo Shows Early, Promising Activity in IDH2-Mutant AML

November 23, 2021

The combination of enasidenib plus azacitidine was well tolerated and induced significantly improved response rates compared with azacitidine alone in patients with newly diagnosed, IDH2-mutant acute myeloid leukemia.

Treatment Sequencing Could Change With Complementary Combinations and CAR T Options in B-ALL

November 05, 2021

Significant progress with rapidly evolving therapies, including blinatumomab, inotuzumab ozogamicin, and CAR T-cell therapy, has been made to extend the median overall survival and improve outcomes for patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

MRD Continues to Show Prognostic Potential in AML and Shape Treatment Decisions

November 03, 2021

Newer modalities are exploring ways to provide more specificity on the value of minimal residual disease negativity in acute myeloid leukemia, since currently there is little definitive action that can be taken with the marker in clinical practice, according to Naval Daver, MD.